Medifron DBT Co. Ltd
Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD… Read more
Medifron DBT Co. Ltd (065650) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.472x
Based on the latest financial reports, Medifron DBT Co. Ltd (065650) has a cash flow conversion efficiency ratio of -0.472x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-12.73 Billion) by net assets (₩27.00 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medifron DBT Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Medifron DBT Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Medifron DBT Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medifron DBT Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Iktinos Hellas S.A. Greek Marble Industry Technical and Touristic Company
AT:IKTIN
|
-0.030x |
|
Becker Milk Co Ltd Cl B Nv Spec (BEK-B.TO
TO:BEK-B
|
0.018x |
|
IT Link
PA:ALITL
|
0.065x |
|
LiqTech International Inc
NASDAQ:LIQT
|
-0.084x |
|
Pungkang Co. Ltd
KQ:093380
|
0.021x |
|
TRC Construction Public Company Limited
BK:TRC
|
0.069x |
|
Masterkool International Public Company Limited
BK:KOOL
|
-0.034x |
|
MClean Technologies Bhd
KLSE:0167
|
0.089x |
Annual Cash Flow Conversion Efficiency for Medifron DBT Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Medifron DBT Co. Ltd from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩17.49 Billion | ₩-4.54 Billion | -0.259x | -347.44% |
| 2023-12-31 | ₩36.89 Billion | ₩-2.14 Billion | -0.058x | +38.16% |
| 2022-12-31 | ₩31.09 Billion | ₩-2.91 Billion | -0.094x | -163.79% |
| 2021-12-31 | ₩42.29 Billion | ₩-1.50 Billion | -0.036x | +40.87% |
| 2020-12-31 | ₩27.86 Billion | ₩-1.67 Billion | -0.060x | +75.19% |
| 2019-12-31 | ₩17.69 Billion | ₩-4.28 Billion | -0.242x | -445.39% |
| 2018-12-31 | ₩19.20 Billion | ₩-852.48 Million | -0.044x | +6.08% |
| 2017-12-31 | ₩24.75 Billion | ₩-1.17 Billion | -0.047x | -4.98% |
| 2016-12-31 | ₩25.57 Billion | ₩-1.15 Billion | -0.045x | -529.58% |
| 2015-12-31 | ₩23.80 Billion | ₩-170.27 Million | -0.007x | -25520.44% |
| 2014-12-31 | ₩24.94 Billion | ₩701.96K | 0.000x | -- |